Regarding AMD treatment, bevacizumab was administered to 325 (27.9%) patients, ranibizumab to 331 (28.4%), and aflibercept to 626 (53.8%); 115 patients received two anti-VEGF treatments, while 90 did not receive any. The gene discussed is VEGFA; the disease is age-related macular degeneration.